Tyrosine Kinase Inhibitor

SAN DIEGO — Kathryn Dao, MD, discusses a study presented at ACR Convergence 2023 that compared the initiation of TNF inhibitors with non-TNF inhibitor biologics or JAK inhibitors among patients with rheumatoid arthritis-associated interstitial lung disease.

MADRID — In a video interview with Healio, Sumanta (Monty) Pal, MD, FASCO, spoke about the STELLAR-304 clinical trial for patients with non-clear cell renal cell carcinoma at ESMO Congress.

Healio spoke with Gwen Nichols, MD, to discuss survivorship in CML patients.

Healio spoke with Gwen Nichols, MD, to discuss how to approach CML treatment in pediatric patients.

Healio spoke with Gwen Nichols, MD, about treatment options currently available in CML.

In this Healio Video Perspective, Sophie J. Bakri, MD, discusses data presented at the Retina Society meeting that investigated the antiangiogenic profiles of three tyrosine kinase inhibitors: vorolanib, axitinib and sunitinib.

In this video, Diana Do, MD, Professor of Ophthalmology at the Stanford University School of Medicine, discusses the 'bright future' for DME treatment with new drugs coming down the pipeline.

Treatment with immediate release tablets of a non-covalent Bruton’s tyrosine kinase inhibitor for relapsing forms of multiple sclerosis met pharmacokinetic and pharmacodynamic goals, data show.

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting.

Healio spoke with Charu Aggarwal, MD, MPH, about data from the Keynote-789 trial presented at this year’s ASCO Annual Meeting.